{
  "items": "39",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.zanesvilletimesrecorder.com/press-release/story/13927/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251211T031038",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics and Nova Minerals Limited on their \"Small Stocks, Big Money\u2122\" show on Bloomberg TV. Calidi Biotherapeutics' CEO will discuss their RedTail platform for precision genetic medicine targeting cancer, while Nova Minerals' CEO will outline their strategy for the Estelle Project in Alaska, focusing on gold and antimony production. Both companies are clients of RedChip, and the interviews offer insights into their respective market opportunities and growth strategies.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Zanesville Times Recorder",
      "category_within_source": "General",
      "source_domain": "Zanesville Times Recorder",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905179"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.820459"
        }
      ],
      "overall_sentiment_score": 0.209232,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.450642",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NEM",
          "relevance_score": "0.580098",
          "ticker_sentiment_score": "0.118312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.558681",
          "ticker_sentiment_score": "0.148755",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.562638",
          "ticker_sentiment_score": "0.140831",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.wrbl.com/business/press-releases/accesswire/1114995/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv",
      "time_published": "20251208T050857",
      "authors": [
        "NULL"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. and Nova Minerals Limited on its \"RedChip Small Stocks, Big Money\u2122\" show on Bloomberg TV. Calidi Biotherapeutics' CEO will discuss their RedTail platform for precision genetic medicine targeting cancer and autoimmune diseases, while Nova Minerals' CEO will outline the strategy for their Estelle Project, a significant gold and critical minerals asset in Alaska. The interviews will air on Saturday, December 6th, at 7 p.m. ET, highlighting both companies' growth potential and strategic initiatives.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "WRBL",
      "category_within_source": "General",
      "source_domain": "WRBL",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900272"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843465"
        },
        {
          "topic": "finance",
          "relevance_score": "0.703990"
        }
      ],
      "overall_sentiment_score": 0.240809,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.521403",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NEM",
          "relevance_score": "0.649230",
          "ticker_sentiment_score": "0.126040",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.626088",
          "ticker_sentiment_score": "0.115621",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LMT",
          "relevance_score": "0.644141",
          "ticker_sentiment_score": "0.100414",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.yourcentralvalley.com/business/press-releases/accesswire/1114995/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv",
      "time_published": "20251208T050857",
      "authors": [
        "NULL"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (NYSE American: CLDI) and Nova Minerals Limited (Nasdaq: NVA) on its \"Small Stocks, Big Money\" show on Bloomberg TV. Calidi Biotherapeutics' CEO will discuss its RedTail platform for treating metastatic tumors, while Nova Minerals' CEO will outline the strategy for its Estelle Project, a significant gold and critical minerals asset in Alaska. The show will air on December 6, 2025, at 7 p.m. ET.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "yourcentralvalley.com",
      "category_within_source": "General",
      "source_domain": "yourcentralvalley.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909586"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.847386"
        },
        {
          "topic": "finance",
          "relevance_score": "0.726105"
        }
      ],
      "overall_sentiment_score": 0.442434,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.408826",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.lubbockonline.com/press-release/story/114305/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251208T030916",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "Calidi Biotherapeutics (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) will be featured on the RedChip Small Stocks, Big Money\u2122 show on Bloomberg TV this Saturday, December 6, at 7 p.m. ET. Calidi's CEO will discuss their RedTail platform for precision genetic medicine targeting oncology and autoimmune diseases, while Nova Minerals' CEO will detail the strategy for its Estelle Project in Alaska, focusing on gold production and antimony supply. Both companies are clients of RedChip Companies, which facilitates their interviews to showcase their advancements and market potential.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Lubbock Avalanche-Journal",
      "category_within_source": "General",
      "source_domain": "Lubbock Avalanche-Journal",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.879100"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.809504"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.768610"
        }
      ],
      "overall_sentiment_score": 0.402716,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404777",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.heraldmailmedia.com/press-release/story/37394/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T070938",
      "authors": [
        "RedChip Companies",
        "Inc."
      ],
      "summary": "Calidi Biotherapeutics (NYSE American: CLDI) and Nova Minerals Limited (Nasdaq: NVA) will have interviews aired on the \"RedChip Small Stocks, Big Money\u2122\" show on Bloomberg TV this Saturday, December 6, at 7 p.m. ET. Calidi's CEO will discuss their RedTail platform for precision genetic medicine, targeting the oncology and autoimmune disease markets, while Nova Minerals' CEO will outline the strategy for their Estelle Project in Alaska, focusing on gold production and antimony supply. Both companies are positioning themselves for significant growth and value creation for shareholders.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "The Herald-Mail",
      "category_within_source": "General",
      "source_domain": "The Herald-Mail",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.833209"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.738510"
        }
      ],
      "overall_sentiment_score": 0.469255,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.493839",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.aberdeennews.com/press-release/story/126058/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T060905",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "Calidi Biotherapeutics (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) will be featured on the RedChip Small Stocks, Big Money\u2122 show on Bloomberg TV. Calidi's CEO, Eric Poma, will discuss their RedTail platform for precision genetic medicine, targeting the growing oncology market. Nova Minerals' CEO, Christopher Gerteisen, will present the strategy for their Estelle Project in Alaska, focusing on gold production and antimony supply, bolstered by a significant Defense Production Act award.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "aberdeennews.com",
      "category_within_source": "General",
      "source_domain": "aberdeennews.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929948"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.735393"
        },
        {
          "topic": "finance",
          "relevance_score": "0.622539"
        }
      ],
      "overall_sentiment_score": 0.467139,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.485320",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.capecodtimes.com/press-release/story/60518/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T055341",
      "authors": [
        "RedChip Companies",
        "Inc."
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (NYSE American: CLDI) and Nova Minerals Limited (Nasdaq: NVA) on its \"RedChip Small Stocks, Big Money\u2122\" show. The program will air on Bloomberg TV on Saturday, December 6, at 7 p.m. ET. The interviews will discuss Calidi's RedTail platform for engineered viral therapy in oncology and Nova Minerals' strategy to advance its Estelle Project in Alaska, including gold production and antimony supply.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Cape Cod Times",
      "category_within_source": "General",
      "source_domain": "Cape Cod Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914801"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.811109"
        },
        {
          "topic": "finance",
          "relevance_score": "0.730675"
        }
      ],
      "overall_sentiment_score": 0.491083,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.484322",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.lancastereaglegazette.com/press-release/story/12378/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T050859",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip Small Stocks, Big Money \u2122 show on Bloomberg TV this Saturday, December 6, at 7 p.m. Eastern Time (ET). Calidi's CEO will discuss their RedTail platform, a pioneering approach to precision genetic medicine targeting the oncology market, while Nova Minerals' CEO will outline its strategy to advance the Estelle Project in Alaska, focusing on gold and antimony resources. Both companies aim to highlight their potential to deliver value to shareholders through innovative strategies and market positioning.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Lancaster Eagle-Gazette",
      "category_within_source": "General",
      "source_domain": "Lancaster Eagle-Gazette",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.839566"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.743248"
        }
      ],
      "overall_sentiment_score": 0.209621,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.423698",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.601554",
          "ticker_sentiment_score": "0.149021",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NFLX",
          "relevance_score": "0.640783",
          "ticker_sentiment_score": "0.103203",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.640606",
          "ticker_sentiment_score": "0.130698",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.oakridger.com/press-release/story/15290/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T035342",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on its \"RedChip Small Stocks, Big Money\u2122\" show, airing on Bloomberg TV this Saturday, December 6, at 7 p.m. ET. Calidi's CEO, Eric Poma, Ph.D., will discuss their RedTail platform for targeted genetic medicine, while Nova Minerals' CEO, Christopher Gerteisen, will detail the strategy for their Estelle Project, a significant gold and critical minerals asset in Alaska. The interviews will highlight each company's potential for growth and value creation for shareholders.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Oak Ridger",
      "category_within_source": "General",
      "source_domain": "Oak Ridger",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923113"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.722945"
        },
        {
          "topic": "finance",
          "relevance_score": "0.612940"
        }
      ],
      "overall_sentiment_score": 0.288068,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.481046",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NDAQ",
          "relevance_score": "0.614044",
          "ticker_sentiment_score": "0.100637",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.oklahoman.com/press-release/story/120503/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T035341",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on its \"RedChip Small Stocks, Big Money\u2122\" show on Bloomberg TV. Calidi Biotherapeutics CEO Eric Poma will discuss their RedTail platform for precision genetic medicine targeting cancer and autoimmune diseases, while Nova Minerals CEO Christopher Gerteisen will outline the strategy for their Estelle Project in Alaska, focusing on gold and critical minerals. The broadcast is scheduled for December 6, 2025, at 7 p.m. ET.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "The Oklahoman",
      "category_within_source": "General",
      "source_domain": "The Oklahoman",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929737"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.729855"
        },
        {
          "topic": "finance",
          "relevance_score": "0.647836"
        }
      ],
      "overall_sentiment_score": 0.458493,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.487159",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.cjonline.com/press-release/story/9363/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251207T035341",
      "authors": [
        "RedChip Companies",
        "Inc."
      ],
      "summary": "RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip Small Stocks, Big Money\u2122 show this Saturday, December 6, at 7 p.m. Eastern Time (ET) on Bloomberg TV. Calidi Biotherapeutics CEO will discuss their RedTail platform for precision genetic medicine, targeting a vast oncology market, while Nova Minerals CEO will outline their strategy for the Estelle Project in Alaska, focusing on gold production and antimony supply. Both companies aim to highlight their potential and value to shareholders and partners on the program.",
      "banner_image": "https://www.cjonline.com/gciaf/prod/p?a=pageview&p=NTCJ-TEALIUM-COBRAND&m=web&k=f14ebdd6-0569-4c64-af73-99937bc06379&s=noscript&",
      "source": "The Topeka Capital-Journal",
      "category_within_source": "General",
      "source_domain": "The Topeka Capital-Journal",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905510"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.824462"
        },
        {
          "topic": "finance",
          "relevance_score": "0.714633"
        }
      ],
      "overall_sentiment_score": 0.445398,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.405963",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.greenvilleonline.com/press-release/story/92350/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251206T070938",
      "authors": [
        "RedChip Companies",
        "Inc."
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on its \"RedChip Small Stocks, Big Money\u2122\" show. The broadcast, a sponsored program on Bloomberg TV, is scheduled for Saturday, December 6, at 7 p.m. Eastern Time. Calidi's CEO will discuss their precision genetic medicine platform RedTail, while Nova Minerals' CEO will outline the strategy for their Estelle Project in Alaska, focusing on gold and antimony development.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Greenville Online",
      "category_within_source": "General",
      "source_domain": "Greenville Online",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.813830"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.738471"
        },
        {
          "topic": "finance",
          "relevance_score": "0.637336"
        }
      ],
      "overall_sentiment_score": 0.485846,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.460203",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.dispatch.com/press-release/story/131265/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251206T035342",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on its \"RedChip Small Stocks, Big Money\u2122\" show on Bloomberg TV. Calidi's CEO, Eric Poma, will discuss their RedTail platform for precision genetic medicine targeting oncology, while Nova Minerals' CEO, Christopher Gerteisen, will detail the strategy for their Estelle Project in Alaska, focusing on gold and critical minerals. The program is scheduled to air on Saturday, December 6, at 7 p.m. Eastern Time.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "The Columbus Dispatch",
      "category_within_source": "General",
      "source_domain": "The Columbus Dispatch",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905849"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806936"
        }
      ],
      "overall_sentiment_score": 0.427855,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.428901",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://fox2now.com/business/press-releases/accesswire/1114995/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv",
      "time_published": "20251206T035342",
      "authors": [
        "NULL"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on its \"RedChip Small Stocks, Big Money\u2122\" show, airing on Bloomberg TV on December 6th at 7 p.m. ET. Calidi's CEO, Eric Poma, will discuss the company's RedTail platform for targeted genetic medicine in oncology, while Nova Minerals CEO, Christopher Gerteisen, will outline the development strategy for its Estelle Project in Alaska, focusing on gold and critical minerals. Both companies are positioned for significant growth in their respective markets.",
      "banner_image": "https://i0.wp.com/fox2now.com/wp-content/uploads/sites/14/2025/12/AP25300848711506.jpg?w=2000&ssl=1",
      "source": "FOX 2",
      "category_within_source": "General",
      "source_domain": "FOX 2",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912235"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.826515"
        },
        {
          "topic": "finance",
          "relevance_score": "0.735929"
        }
      ],
      "overall_sentiment_score": 0.430577,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404579",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.elpasotimes.com/press-release/story/96814/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251206T035342",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics and Nova Minerals Limited on their \"Small Stocks, Big Money\" show on Bloomberg TV. Calidi's CEO will discuss their RedTail platform for targeted cancer therapies, while Nova Minerals' CEO will outline the strategy for their Estelle Project, a significant gold and critical minerals asset in Alaska. The program aims to highlight the potential of these companies to investors.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "El Paso Times",
      "category_within_source": "General",
      "source_domain": "El Paso Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948059"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.805486"
        },
        {
          "topic": "finance",
          "relevance_score": "0.719490"
        }
      ],
      "overall_sentiment_score": 0.488988,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.499347",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.norwichbulletin.com/press-release/story/15215/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251206T031032",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will air interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the \"RedChip Small Stocks, Big Money\u2122\" show. The program will be broadcast on Bloomberg TV on Saturday, December 6, at 7 p.m. Eastern Time. Both companies will discuss their innovative approaches in precision genetic medicine and gold/critical minerals development, respectively.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Norwich Bulletin",
      "category_within_source": "General",
      "source_domain": "Norwich Bulletin",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.911794"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.825338"
        },
        {
          "topic": "finance",
          "relevance_score": "0.718197"
        }
      ],
      "overall_sentiment_score": 0.709619,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.983810",
          "ticker_sentiment_score": "0.722020",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://www.goerie.com/press-release/story/47088/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv/",
      "time_published": "20251206T031032",
      "authors": [
        "RedChip Companies",
        "Inc. (Media Suite)"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (NYSE American: CLDI) and Nova Minerals Limited (Nasdaq: NVA) on its \"RedChip Small Stocks, Big Money(TM)\" show on Bloomberg TV this Saturday, December 6, at 7 p.m. ET. Calidi's CEO, Eric Poma, Ph.D., will discuss the company's RedTail platform for precision genetic medicine targeting cancer and autoimmune diseases, while Nova Minerals' CEO, Christopher Gerteisen, will outline the strategy for their Estelle Project, a significant gold and critical minerals asset in Alaska. The interviews highlight the companies' growth potential and strategic initiatives.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1114995",
      "source": "Erie Times-News",
      "category_within_source": "General",
      "source_domain": "Erie Times-News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904997"
        },
        {
          "topic": "finance",
          "relevance_score": "0.806419"
        }
      ],
      "overall_sentiment_score": 0.429197,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436616",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV",
      "url": "https://fox40.com/business/press-releases/accesswire/1114995/calidi-biotherapeutics-and-nova-minerals-interviews-to-air-on-the-redchip-small-stocks-big-moneytm-show-on-bloomberg-tv",
      "time_published": "20251205T090000",
      "authors": [
        "NULL"
      ],
      "summary": "RedChip Companies will feature interviews with Calidi Biotherapeutics, Inc. (CLDI) and Nova Minerals Limited (NVA) on its \"RedChip Small Stocks, Big Money\" show airing on Bloomberg TV. Calidi Biotherapeutics will discuss its RedTail platform for precision genetic medicine targeting cancer and autoimmune diseases, aiming for IND filing by late 2026. Nova Minerals will present its strategy for the Estelle Project in Alaska, focusing on advancing its gold resources and establishing a domestic antimony supply chain, supported by a US$43.4 million Defense Production Act award.",
      "banner_image": "https://i0.wp.com/fox40.com/wp-content/uploads/sites/13/2025/10/GettyImages-943697000-1-1-3-2-2-e1697928619486-1-e1698682964713-1_92da3b-e1743430271414_864bd0.jpg?w=2000&ssl=1",
      "source": "FOX40 News",
      "category_within_source": "General",
      "source_domain": "FOX40 News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921855"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.820376"
        },
        {
          "topic": "finance",
          "relevance_score": "0.733750"
        }
      ],
      "overall_sentiment_score": 0.468464,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.479656",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025",
      "url": "https://finance.yahoo.com/news/calidi-biotherapeutics-announces-exclusive-live-130000064.html",
      "time_published": "20251120T060905",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is hosting a live investor webinar and Q&A session on November 19, 2025, featuring CEO Eric Poma, Ph.D. The event, hosted by RedChip Companies, will focus on Calidi's RedTail platform, a pioneering approach to precision genetic medicine for metastatic cancer, and the company's financial updates. Attendees can register for the free webinar to learn more about the company's progress toward IND filing and its potential in the oncology market.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906065"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.937295"
        },
        {
          "topic": "finance",
          "relevance_score": "0.635599"
        }
      ],
      "overall_sentiment_score": 0.391235,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.383771",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics (CLDI) Details RedTail, $560B Oncology Webinar Nov. 19",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-announces-exclusive-live-investor-webinar-and-3e3at24dnm5o.html",
      "time_published": "20251117T050857",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics (NYSE American: CLDI) is hosting an exclusive live investor webinar and Q&A on November 19, 2025, to discuss its RedTail platform, progress towards IND filing by late 2026, and Q3 2025 financial results. The webinar will highlight preclinical data showcasing RedTail's systemic delivery and tumor-targeted replication, positioning the company to address a projected $560 billion oncology market. Investors are invited to register for the free event, which will include a live Q&A session with CEO Eric Poma, Ph.D.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.929650"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.902241"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.724272"
        },
        {
          "topic": "finance",
          "relevance_score": "0.632238"
        }
      ],
      "overall_sentiment_score": 0.327884,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.318842",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics (NYSE American: CLDI) to showcase RedTail, CLD-401 at SITC Nov 7",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-announces-investor-event-to-be-held-on-friday-c9f16akiinrj.html",
      "time_published": "20251116T050837",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics will host an investor event on November 7, 2025, at the SITC Annual Meeting to showcase its RedTail platform and lead candidate CLD-401. The event will feature key scientific and leadership personnel and will be live-streamed. Calidi is currently conducting IND-enabling studies for CLD-401 and aims to submit an Investigational New Drug application by the end of 2026, while also exploring strategic partnerships.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932740"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.711691"
        }
      ],
      "overall_sentiment_score": 0.140169,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.107903",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi (NYSE American: CLDI) closes $6.9M offering; third-quarter net loss $5.2M",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-reports-third-quarter-2025-financial-results-gxsst9zpr17l.html",
      "time_published": "20251115T050857",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics reported its Q3 2025 financial results, including a net loss of $5.2 million, which increased to $10.8 million attributable to shareholders due to a non-cash deemed-warrant-dividend charge. The company also announced the closing of a $6.9 million public offering, bringing total 2025 gross proceeds to $23.0 million, and presented positive preclinical data for its RedTail platform and lead candidate CLD-401. This data highlighted the platform's ability to protect against immune clearance and deliver genetic payloads to metastatic tumor sites.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.940936"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.938145"
        },
        {
          "topic": "finance",
          "relevance_score": "0.747772"
        }
      ],
      "overall_sentiment_score": 0.128535,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.123549",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting",
      "url": "https://finance.yahoo.com/news/calidi-biotherapeutics-announces-data-presented-120000530.html",
      "time_published": "20251114T050859",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics announced that new data on its therapeutic lead, CLD-401, will be presented at the 2025 SITC Annual Meeting. CLD-401 is an oncolytic virus from their RedTail platform designed to target metastatic sites, induce immune priming, and deliver an IL-15 superagonist. The company is conducting IND-enabling studies for CLD-401, aiming for an IND application by late 2026, and is seeking strategic partnerships.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/ZzRllEwmBJRmtO.L0Gf1ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924360"
        }
      ],
      "overall_sentiment_score": 0.455326,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.491526",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND",
      "url": "https://www.prnewswire.com/news-releases/matica-bio-a-cdmo-leader-in-oncolytic-virus-manufacturing-partners-with-calidi-biotherapeutics-to-advance-calidis-project-toward-ind-302600781.html",
      "time_published": "20251103T080000",
      "authors": [],
      "summary": "Matica Bio, a viral vector CDMO, has partnered with Calidi Biotherapeutics, a clinical-stage immuno-oncology company, to support the IND submission for Calidi's CLD-401, a next-generation oncolytic virus. Matica Bio will provide analytical development, process development, and GMP manufacturing for CLD-401, which is designed to target metastatic cancer sites and deliver an IL-15 superagonist. This collaboration highlights Matica Bio's expertise in oncolytic virus manufacturing and its role in advancing innovative cancer immunotherapies.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.845950"
        }
      ],
      "overall_sentiment_score": 0.645585,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.635640",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters\u2019 Over-Allotment Option",
      "url": "https://finance.yahoo.com/news/calidi-biotherapeutics-announces-closing-6-223300904.html",
      "time_published": "20250821T060915",
      "authors": [
        "Calidi Biotherapeutics",
        "Inc"
      ],
      "summary": "Calidi Biotherapeutics announced the closing of its previously declared underwritten public offering, raising $6.9 million before deductions. This offering also included the full exercise of the underwriters' over-allotment option. The funds were generated through the sale of common stock units and pre-funded warrant units.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/ZzRllEwmBJRmtO.L0Gf1ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.937082"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.946940"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.805318"
        },
        {
          "topic": "finance",
          "relevance_score": "0.725730"
        }
      ],
      "overall_sentiment_score": 0.337116,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.330297",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering",
      "url": "https://www.globenewswire.com/news-release/2025/08/20/3136482/0/en/Calidi-Biotherapeutics-Announces-Pricing-of-6-Million-Underwritten-Public-Offering.html",
      "time_published": "20250820T091500",
      "authors": [],
      "summary": "Calidi Biotherapeutics, Inc. announced the pricing of a $6 million underwritten public offering, which included participation from current shareholders, new investors, management, and board members. The offering is comprised of Common Stock Units and Pre-Funded Units, with an option for underwriters to purchase additional shares and/or warrants. This capital aims to further the company's development of targeted therapies using its Redtail platform for systemic delivery of genetic medicines.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.905901"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807214"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.748215"
        }
      ],
      "overall_sentiment_score": 0.116072,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.122988",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clinical-Stage Biotech Calidi Raises $4.6M in Fresh Capital: Accelerates Targeted Therapy Programs",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-announces-exercise-of-warrants-for-4-6-5nv0h24x4w9p.html",
      "time_published": "20250709T140100",
      "authors": [],
      "summary": "Calidi Biotherapeutics (NYSE American: CLDI) has secured approximately $4.6 million in gross proceeds through the exercise of multiple series of warrants at a reduced price of $0.70 per share. The company will issue new unregistered warrants for an equivalent number of shares, exercisable after six months with a 5.5-year term. The proceeds are designated to advance clinical and pre-clinical programs, cover operating expenses, and provide working capital, with Ladenburg Thalmann & Co. acting as the exclusive placement agent.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.903158"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.844761"
        }
      ],
      "overall_sentiment_score": 0.274195,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.973955",
          "ticker_sentiment_score": "0.265015",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Stock Jumps 39% After Hours \u2014 What's Going On",
      "url": "https://www.benzinga.com/markets/equities/25/07/46311837/calidi-biotherapeutics-stock-jumps-39-after-hours-whats-going-on",
      "time_published": "20250709T000900",
      "authors": [
        "Mohd Haider"
      ],
      "summary": "Calidi Biotherapeutics (AMEX:CLDI) stock surged significantly in after-hours trading due to investor confidence in its innovative cancer treatments. The surge comes amidst broader developments in the healthcare sector, including Mustang Bio (NASDAQ:MBIO) also experiencing a substantial stock increase after a key FDA designation. Investors are closely monitoring the biotech industry for such opportunities.",
      "banner_image": null,
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "Benzinga",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941503"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.823945"
        }
      ],
      "overall_sentiment_score": 0.602475,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.613228",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment",
      "url": "https://finance.yahoo.com/news/calidi-biotherapeutics-inc-nyse-american-123000824.html",
      "time_published": "20250708T123000",
      "authors": [],
      "summary": "Calidi Biotherapeutics Inc. (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment, utilizing engineered viruses and allogeneic stem cells to target and attack tumors. The company aims to revolutionize cancer treatment by delivering potent genetic medicines to both primary and metastatic cancer sites. This approach addresses the significant unmet need for more effective cancer drugs, with cancer diagnoses projected to reach 35 million annually by 2050.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.497175,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.459495",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights",
      "url": "https://www.globenewswire.com/news-release/2025/05/14/3081650/0/en/Calidi-Biotherapeutics-Reports-First-Quarter-2025-Financial-Results-and-Recent-Operational-Highlights.html",
      "time_published": "20250514T163000",
      "authors": [],
      "summary": "Calidi Biotherapeutics reported its first quarter 2025 financial results and highlighted recent operational achievements, including key executive hires, significant preclinical data for its Redtail platform, and FDA clearance for its CLD-201 clinical trial. The company experienced a reduced net loss attributable to common stockholders and maintained a strong cash position. These developments position Calidi for further advancements in its systemic oncolytic targeted immunotherapies.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908614"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.801715"
        }
      ],
      "overall_sentiment_score": 0.414806,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.418708",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director",
      "url": "https://finance.yahoo.com/news/calidi-biotherapeutics-announces-chief-executive-120000838.html",
      "time_published": "20250423T040924",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics announced a CEO transition, with Allan Camaisa stepping down and Eric Poma, Ph.D., appointed as the new CEO and a Board member, effective April 22, 2025. Dr. Poma brings extensive experience in the biopharmaceutical industry, particularly in oncology, capital fundraising, and strategic collaborations. His appointment aligns with Calidi's advancements in its systemic enveloped virotherapy platform and ongoing clinical programs.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.447763,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.424718",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement",
      "url": "https://www.globenewswire.com/news-release/2025/03/31/3052809/0/en/Calidi-Biotherapeutics-Announces-Closing-of-3-9-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement.html",
      "time_published": "20250331T163000",
      "authors": [],
      "summary": "Calidi Biotherapeutics announced the closing of a registered direct offering and concurrent private placement, raising approximately $3.9 million. The offering included the sale of common stock and pre-funded warrants, along with Series G common warrants to an institutional investor. The net proceeds will be used for working capital, general corporate purposes, and to advance preclinical and clinical programs.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.938008"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.838747"
        },
        {
          "topic": "finance",
          "relevance_score": "0.736607"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.603086"
        }
      ],
      "overall_sentiment_score": 0.335691,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.318362",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-reports-fourth-quarter-and-full-year-2024-ql7p9q3lzjsa.html",
      "time_published": "20250331T161000",
      "authors": [],
      "summary": "Calidi Biotherapeutics (NYSE: CLDI) announced its Q4 and full-year 2024 financial results, reporting a significant reduction in net loss while advancing its cancer gene therapy trials. Key developments include filing an IND for CLD-201 Phase 1 trial for multiple solid tumors, advancing recruitment for a Phase 1 trial at Northwestern University for high-grade glioma, and enrolling 14 patients in a City of Hope Phase 1 trial for recurrent high-grade glioma. The company ended 2024 with $9.6 million in cash, demonstrating improved financial efficiency.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.927976"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.930489"
        }
      ],
      "overall_sentiment_score": 0.45906,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.451004",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Calidi Biotherapeutics (CLDI) Stock Is Getting Hammered",
      "url": "https://www.tradingview.com/news/benzinga:d2987c07d094b:0-why-calidi-biotherapeutics-cldi-stock-is-getting-hammered/",
      "time_published": "20241231T235959",
      "authors": [
        "NULL"
      ],
      "summary": "Calidi Biotherapeutics stock (CLDI) fell over 30% after announcing a definitive agreement for the immediate exercise of Series B and C warrants. This exercise, expected to generate $2.1 million, involves current warrant holders exercising their options and receiving new unregistered warrants. The proceeds will fund the company's clinical and pre-clinical programs, operating expenses, and working capital.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.933381"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.809664"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.631688"
        }
      ],
      "overall_sentiment_score": 0.002448,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.339519",
          "ticker_sentiment_score": "0.038233",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics Faces Market Turmoil: Is Recovery On The Horizon?",
      "url": "https://www.timothysykes.com/news/calidi-biotherapeutics-inc-cldi-news-2024_11_14/",
      "time_published": "20241114T091800",
      "authors": [
        "Timothy Sykes",
        "Jack Kellogg",
        "Ellis Hobbs"
      ],
      "summary": "Calidi Biotherapeutics Inc. (CLDI) experienced a significant stock price downturn, falling by -18.62% following the announcement and pricing of a $2M direct offering and parallel private placement. The company faces financial struggles, evidenced by a Q3 2024 net loss of approximately $5.069 million and negative diluted EPS, compounded by delisting proceedings for its warrants on the NYSE American. Its future hinges on effective financial maneuvers and leveraging biotech expertise to regain market confidence and achieve stability amidst turbulent times.",
      "banner_image": "https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2024/11/watermarked_CLDI_2024-11-14T09-18.png",
      "source": "www.timothysykes.com",
      "category_within_source": "General",
      "source_domain": "www.timothysykes.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.903899"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.846504"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.743954"
        },
        {
          "topic": "finance",
          "relevance_score": "0.607288"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.408557"
        }
      ],
      "overall_sentiment_score": 0.03634,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.346065",
          "ticker_sentiment_score": "0.039109",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-to-present-data-supporting-rt-nova-at-jtxed750ztso.html",
      "time_published": "20241024T083000",
      "authors": [],
      "summary": "Calidi Biotherapeutics (NYSE: CLDI) will present data supporting its systemic antitumor virotherapy platform, RTNova, at three major scientific conferences in October and November 2024. RTNova is designed to target multiple tumor sites, kill cancer cells, and modify the tumor immune microenvironment, offering a potential treatment for previously untreatable metastatic diseases. The presentations will be led by Dr. Antonio Santidrian and Dr. Duong Nguyen, highlighting the platform's ability to revolutionize cancer therapy.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.030342,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.313889",
          "ticker_sentiment_score": "0.042270",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-inc-announces-closing-of-6-1-million-public-yiuzan8yhvv5.html",
      "time_published": "20240419T160500",
      "authors": [],
      "summary": "Calidi Biotherapeutics, Inc. announced the closing of a public offering that raised approximately $6.1 million in gross proceeds. The offering included 15,197,500 shares of common stock (or pre-funded warrants) and accompanying warrants, priced at $0.40 per unit. The company plans to use the net proceeds for working capital, general corporate purposes, pre-clinical and clinical trials, and debt repayment.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.702054"
        }
      ],
      "overall_sentiment_score": 0.012758,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.342456",
          "ticker_sentiment_score": "0.019144",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer\u2019s 38th Annual Meeting (SITC 2023)",
      "url": "https://www.stocktitan.net/news/CLDI/calidi-biotherapeutics-nyseam-cldi-presents-data-on-cld-201-9llq5dmbqkpc.html",
      "time_published": "20231103T070000",
      "authors": [],
      "summary": "Calidi Biotherapeutics presented new preclinical data on its CLD-201 (SuperNova) platform at SITC 2023, showcasing its ability to inhibit tumor growth and induce robust anti-tumor immunity. The data supports CLD-201's potential as an allogeneic solution for solid tumors, demonstrating enhanced resistance to immune inactivation and promising anti-tumor effects in animal models. Calidi plans to initiate a Phase 1 clinical trial for CLD-201 in 2024.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.491432,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.480045",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Calidi goes public via SPAC with $70M lined up to push allogeneic cancer therapies into clinic",
      "url": "https://www.fiercebiotech.com/biotech/calidi-goes-public-spac-70m-lined-push-allogeneic-cancer-therapies-clinic",
      "time_published": "20230913T093500",
      "authors": [
        "James Waldron"
      ],
      "summary": "Calidi Biotherapeutics has gone public via a SPAC merger with First Light Acquisition Group, securing nearly $70 million in funds to advance its allogeneic stem cell cancer therapies. The company is poised to debut on the NYSE American stock exchange and aims to fund operations into 2025 with its clinical assets, CLD-101 and CLD-201, in development for various cancers. This move marks Calidi as another biotech utilizing the blank-check route to public markets.",
      "banner_image": null,
      "source": "Fierce Biotech",
      "category_within_source": "General",
      "source_domain": "Fierce Biotech",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "0.924603"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.839541"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.739764"
        },
        {
          "topic": "finance",
          "relevance_score": "0.645223"
        }
      ],
      "overall_sentiment_score": 0.019487,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CLDI",
          "relevance_score": "0.314730",
          "ticker_sentiment_score": "0.015199",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}